Vibrato Aspiration System - Simple, Intuitive Approach to Clot Removal in Acute Pulmonary Embolism - a Safety & Feasibility Study
研究概览
详细说明
The study objective is to evaluate the safety and effectiveness of the Vibrato™ Aspiration System Aspiration System (hereafter referred to as Vibrato™ Aspiration System) for aspiration mechanical thrombectomy in the treatment of acute PE.
The Vibrato™ Aspiration System is a vibration-assisted aspiration thrombectomy device including attributes designed to improve trackability, maintain a low-profile configuration, and operate without capital equipment. In addition, the Vibrato™ Aspiration System features a novel vibrating distal tip designed to enhance thrombus removal during aspiration while minimizing vascular injury. The vibrating mechanism may reduce procedure times, improve clot removal efficiency, and decrease the need for adjunctive interventions.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Shawn M Patterson
- 电话号码:7164323545
- 邮箱:spatterson@egrethealthcareventure.com
研究联系人备份
- 姓名:Erin M Garcia
- 电话号码:716-863-2552
- 邮箱:egarcia@egrethealthcareventures.com
学习地点
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、波兰、61-848
- 尚未招聘
- Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Uniwersytecki Szpital Kliniczny
-
首席研究员:
- Aleksander Araszkiewicz, Professor, MD, PhD
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、波兰、31-202
- 招聘中
- Krakowski Szpital Specjalistyczny im. św. Jana Pawła II
-
首席研究员:
- Grzegorz Kopeć, Professor, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
Subjects must meet all following general inclusion criteria:
- Age ≥ 18 and ≤ 75 years.
- Clinical signs, symptoms, and presentation consistent with acute PE;
- PE symptom duration ≤ 14 days;
- CTA evidence (site determined) of proximal PE (filling defect in at least one main or interlobar pulmonary artery)
- RV/LV ratio of ≥ 0.9 on CTA as assessed by investigator (site determined).
- Systolic blood pressure ≥ 90 mmHg;
- Stable heart rate < 130 BPM prior to procedure;
- Patient is deemed medically eligible for interventional procedure(s), per institutional guidelines and clinical judgment
- Informed Consent Form signed
- Subject is willing and able to comply with all Clinical Investigation Plan required follow-up visit
Exclusion Criteria:
Subjects must not meet any of the following general exclusion criteria:
- Thrombolytic use within 30 days of baseline CT angiogram
- Pulmonary hypertension with peak pulmonary artery pressure > 70 mmHg by right heart catheterization (site determined)
- Vasopressor requirement after fluids to keep pressure ≥ 90 mmHg;
- FiO2 requirement > 40% or > 6 LPM to keep oxygen saturation > 90%;
- Hematocrit < 28%;
- Platelets < 100,000/ML;
- Serum creatinine > 1.8 mg/dL;
- International normalized ratio (INR) > 3;
- Major trauma injury severity score (ISS) > 15 within the past 14 days
- Presence of intracardiac lead in the right ventricle or right atrium placed within 6 months, Pacemaker or Implantable Cardioverter Defibrillators;
- Cardiovascular or pulmonary surgery within last 7 days;
- Actively progressing cancer requiring chemotherapy
- Known bleeding diathesis or coagulation disorder;
- Left bundle branch block;
- History of severe or chronic pulmonary arterial hypertension;
- History of chronic left heart disease with left ventricular ejection fraction ≤ 30%;
- History of uncompensated heart failure;
- History of underlying lung disease that is oxygen dependent;
- History of chest irradiation;
- History of heparin-induced thrombocytopenia (HIT);
- Patients who are under intubation
- Any contraindication to systemic or therapeutic doses of heparin or anticoagulants;
- Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated;
- Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the Subject is not appropriate for mechanical thrombectomy intervention;
- Life expectancy of < 90 days, as determined by Investigator;
- Female who is pregnant or nursing;
- Current participation in another investigational drug or device treatment study
- History of Hemorrhagic or Ischemic Stroke, including Transient Ischemic Attack, within last 90 days
- Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
学习计划
研究是如何设计的?
设计细节
- 主要用途:设备可行性
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Single arm study
Vibrato™ Aspiration System for aspiration mechanical thrombectomy in the treatment of acute pulmonary embolism.
|
Mechanical Thrombectomy for the treatment of Acute Pulmonary Embolism
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety Endpoint: Major Adverse Events
大体时间:48 hours
|
Major Adverse Events, a composite of:
|
48 hours
|
|
Efficacy Endpoint: Reduction in RV/LV Ratio
大体时间:48 hours
|
Reduction in RV/LV ratio from baseline to 48 hours or discharge by CT angiography
|
48 hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety Endpoint: Device-Related Death
大体时间:48 hours
|
Device-related death within 48 hours
|
48 hours
|
|
Safety Endpoint: Major Bleeding
大体时间:48 Hours
|
Major bleeding within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Clinical Deterioration
大体时间:48 Hours
|
Device-related clinical deterioration within 48 hours
|
48 Hours
|
|
Safety Endpoint: Device-Related Pulmonary Vascular Injury
大体时间:48 Hours
|
Device-related pulmonary vascular injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Cardiac Injury
大体时间:48 Hours
|
Cardiac injury within 48 hours
|
48 Hours
|
|
Safety Endpoint: Any-Cause Mortality
大体时间:30 Days
|
Any-cause mortality within 30 days
|
30 Days
|
|
Safety Endpoint: Device-Related Serious Adverse Event
大体时间:30 Days
|
Device-related Serious Adverse Events (SAEs) within 30 days
|
30 Days
|
|
Safety Endpoint: Symptomatic Recurrence of Pulmonary Embolism
大体时间:30 Days
|
Symptomatic recurrence of Pulmonary Embolism (PE) within 30 days
|
30 Days
|
|
Efficacy Endpoint: Modified Miller Index Score
大体时间:48 Hours
|
Change in modified Miller Index Score (MMIS) between baseline and 48 hours post-procedure as assessed by CTA
|
48 Hours
|
|
Efficacy Endpoint: Change in Mean Pulmonary Artery Pressure
大体时间:Procedure
|
Change in mean pulmonary artery pressure measured invasively in the central pulmonary arteries before vs. after the endovascular procedure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Change in Cardiac Index
大体时间:Procedure
|
Procedural change in cardiac index [measured in L/min/m^2]
|
Procedure
|
|
Efficacy Endpoint: Length of ICU Stay, Associated with Index Procedure
大体时间:30 Days
|
Length of stay in the ICU associated with the index procedure [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Length of Total Hospital Stay
大体时间:30 Days
|
Length of total hospital stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Post-Index Procedure Hospital Length of Stay
大体时间:30 Days
|
Post-index-procedure hospital length of stay [measured in days]
|
30 Days
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Mean Pressure
大体时间:Procedure
|
Procedural reduction in pulmonary artery mean pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Procedural Reduction in Pulmonary Artery Systolic Pressure
大体时间:Procedure
|
Procedural reduction in pulmonary artery systolic pressure [measured in mmHg]
|
Procedure
|
|
Efficacy Endpoint: Reduction in Total Pulmonary Vascular Resistance
大体时间:Procedure
|
Procedural reduction in total pulmonary vascular resistance [measured in mmHg ⋅ min/L]
|
Procedure
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
大体时间:48 Hours
|
Change from baseline in Dyspnea severity by mMRC score at the 48-hour visit
|
48 Hours
|
|
Efficacy Endpoint: Change from Baseline in Dyspnea Severity by mMRC Score
大体时间:30 Days
|
Change from baseline in Dyspnea severity by mMRC score [Time Frame: at the 30 days visit]
|
30 Days
|
合作者和调查者
赞助
合作者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.